Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Jaguar Health, Inc. (JAGX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2018
2020
2021
2022
2024
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M | $9.4M | $5.8M | $4.4M | $4.4M | $141,523 | $258,381 | $0 |
| Research & development | $25.0M | $16.5M | $18.6M | $17.6M | $15.1M | $6.4M | $5.8M | $5.2M | $4.3M | $7.2M | $6.5M | $4.2M |
| Operating expenses | — | — | — | — | — | — | — | $35.2M | $38.6M | $13.7M | $12.7M | $8.3M |
| Operating income | −$45.9M | −$30.8M | −$34.3M | −$34.4M | −$40.7M | −$26.6M | −$28.9M | −$30.8M | −$34.2M | −$13.6M | −$12.4M | −$8.3M |
| EBITDAderived | −$44.0M | −$28.9M | −$32.3M | −$32.4M | −$39.0M | −$24.9M | −$27.2M | −$29.5M | −$33.7M | −$13.5M | −$12.4M | — |
| Net income | −$53.6M | −$38.5M | −$41,900 | −$48,400 | −$52,600 | −$33.8M | −$38.5M | −$32.1M | −$22.0M | −$14.7M | −$16.3M | −$8.6M |
| Basic EPSper diluted share | -$22.97 | -$130.69 | -$2,678.17 | -$36.18 | -$88.22 | -$3.00 | -$9.01 | -$153.27 | -$7.59 | -$1.35 | -$2.70 | -$3.24 |
| Diluted EPSper diluted share | -$22.97 | -$130.69 | -$2,678.17 | -$36.18 | -$88.22 | -$3.00 | -$9.01 | -$153.27 | -$7.59 | -$1.35 | -$2.70 | -$3.24 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 31, 2025Form 4 | MICEK JOHNDirector | BuyWarrant to Purchase Common Stock · derivative | 9.0K | — | — | 9.0K |
| Mar 31, 2025Form 4 | MICEK JOHNDirector | BuyConvertible Promissory Note · derivative | 9.0K | $50.0K | $450.00M | 9.0K |
| Mar 31, 2025Form 4 | King Steven R.See Remarks | BuyWarrant to Purchase Common Stock · derivative | 3.6K | — | — | 3.6K |
| Mar 31, 2025Form 4 | King Steven R.See Remarks | BuyConvertible Promissory Note · derivative | 3.6K | $20.0K | $72.00M | 3.6K |
| Mar 31, 2025Form 4 | Siegel Jonathan B.Director | BuyWarrant to Purchase Common Stock · derivative · indirect | 9.0K | — | — | 9.0K |